Aerie Pharmaceutical (AERI) 17.35 $AERI
Aerie Pharmaceuticals to Announce Second Quarter 2016 Financial Results and Host Conference Call on Wednesday, August 3, 2016
BusinessWire - Wed Jul 27, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), (the "Company"
, announced today that its second quarter 2016 financial results will be released after the market closes on Wednesday, August 3, 2016. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company's financial results and provide a general business and strategic update.
AERI: 17.35 (-0.19)
Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of Rhopressa(TM)(netarsudil ophthalmic solution) 0.02%
BusinessWire - Thu Jun 16, 5:30AM CDT
---Rocket 4 Designed for EU Filing; Not Required for US NDA Filing-
AERI: 17.35 (-0.19)
Aerie Pharmaceuticals to Participate in Two Investor Conferences in June
BusinessWire - Thu Jun 02, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that company management will present an overview of the company at the following conferences in June.
AERI: 17.35 (-0.19)
Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of Roclatan(TM)(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
BusinessWire - Thu May 05, 5:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced the completion of patient enrollment in the Company's initial Phase 3 registration trial ("Mercury 1" of Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Roclatan(TM) is a fixed dose combination of Aerie drug Rhopressa(TM) (netarsudil ophthalmic solution) 0.02% and latanoprost, the most widely prescribed PGA (prostaglandin analogue). Mercury 1 has total enrollment of approximately 690 patients in this three-arm study, designed to demonstrate superiority of Roclatan(TM) to each of its two components, all dosed once daily in the evening. The range for the primary endpoint evaluates patients with maximum baseline IOPs ranging from above 20 to below 36 mmHg (millimeters of mercury). Mercury 1, which commenced in September 2015 is a twelve-month safety trial with a 90-day interim efficacy readout that is expected in the third quarter of 2016. In March 2016, the Company commenced a second Phase 3 registration trial for Roclatan(TM), Mercury 2, which is a 90-day efficacy trial, and also plans to commence in the first half of 2017 a third Phase 3 clinical trial for Roclatan(TM), named Mercury 3, which will be designed to facilitate regulatory approval and commercialization in Europe.
AERI: 17.35 (-0.19)
Aerie Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
BusinessWire - Wed May 04, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Wednesday, May 11, 2016 at 3:00 p.m. Pacific Time in Las Vegas, NV. Dr. Anido will provide an Aerie overview and business update.
AERI: 17.35 (-0.19)
Aerie (AERI) Q1 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Tue May 03, 7:57AM CDT
Aerie Pharmaceuticals, Inc. (AERI) posted a first-quarter 2016 loss of 85 cents per share, wider than both the Zacks Consensus Estimate of a loss of 66 cents and the year-ago loss of 70 cents.
GILD: 79.47 (-1.77), SHPG: 194.12 (+2.69), AERI: 17.35 (-0.19), AEGR: 1.44 (-0.03)
Aerie reports 1Q loss
Automated Insights - Mon May 02, 3:47PM CDT
IRVINE, Calif. (AP) _ Aerie Pharmaceuticals Inc. (AERI) on Monday reported a loss of $22.7 million in its first quarter.
AERI: 17.35 (-0.19)
Aerie Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Mon May 02, 3:01PM CDT
--Mercury 1 Phase 3 Topline Readout for Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Also Expected in 3Q 2016
AERI: 17.35 (-0.19)
Drug Stocks Q1 Earnings Preview: AEGR, AERI, MACK, PRTA
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:04AM CDT
The going has been quite satisfactory as we stand in the thick of the first earnings season of the year.
MACK: 5.80 (+0.19), BIIB: 289.93 (+0.90), ABT: 44.75 (+0.30), JNJ: 125.23 (+0.77), AERI: 17.35 (-0.19), AEGR: 1.44 (-0.03), PRTA: 55.05 (-0.36)
Aerie (AERI): Can the Stock Pull a Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 5:41PM CDT
Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report first-quarter 2016 results after the market closes on May 2.
GILD: 79.47 (-1.77), AERI: 17.35 (-0.19), AMGN: 172.03 (+0.75), SNY: 42.63 (+0.03)
Aerie Pharmaceuticals to Announce First Quarter 2016 Financial Results and Host Conference Call on Monday, May 2, 2016
BusinessWire - Mon Apr 25, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), (the "Company" , announced today that its first quarter 2016 financial results will be released after the market closes on Monday, May 2, 2016. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company's financial results and provide a general business and strategic update.
AERI: 17.35 (-0.19)
Will Aerie Pharmaceuticals (AERI) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 7:03AM CDT
As of late, it has definitely been a great time to be an investor in Aerie Pharmaceuticals, Inc. (AERI)
AERI: 17.35 (-0.19)
Aerie Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
BusinessWire - Tue Apr 05, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 3:00 p.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.
AERI: 17.35 (-0.19)
Aerie Starts Dosing in Registration Trial Mercury 2 on Roclatan
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 3:25PM CDT
Aerie Pharmaceuticals, Inc. (AERI) announced the initiation of dosing in the second phase III registration trial, Mercury 2, on its pipeline candidate, Roclatan 0.02%/0.005%.
SCMP: 11.75 (+0.07), AERI: 17.35 (-0.19), CORT: 5.80 (-0.06)
Aerie Pharmaceuticals Initiates Second Phase 3 Registration Trial of Roclatan(TM)(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
BusinessWire - Mon Mar 28, 5:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) ("Aerie" or the "Company" , a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on March 24, dosing commenced of the first patients enrolled in Mercury 2, the Company's second Phase 3 registration trial of Roclatan(TM)(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Roclatan(TM) is a fixed dose combination of Aerie product candidate Rhopressa(TM) (netarsudil ophthalmic solution) 0.02% and latanoprost, the most widely prescribed PGA (prostaglandin analogue). Aerie estimates total enrollment of approximately 690 patients in this three-arm 90-day efficacy study, comparing once-daily Roclatan(TM) for superiority to each of its two components, all dosed once daily in the evening. Patients will be evaluated with maximum baseline IOPs ranging from above 20 to below 36 mmHg (millimeters of mercury). The first Phase 3 registration trial for Roclatan(TM), named Mercury 1, commenced in September of 2015. Mercury 1, which is also a superiority trial with the same comparators as Mercury 2, is a 12-month safety trial with a 90-day interim efficacy readout. The Company also plans to commence in the first half of 2017 a third Phase 3 trial for Roclatan(TM), named Mercury 3, which will be for the sole purpose of facilitating regulatory approval and commercialization in Europe.
AERI: 17.35 (-0.19)
Aerie Pharmaceuticals Reports Update on Positive Safety Results for Rhopressa(TM) QD (netarsudil ophthalmic solution) 0.02%
BusinessWire - Thu Mar 17, 3:01PM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported an update including further details on the safety profile for Rhopressa(TM) QD, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The Company previously reported interim topline 12-month safety and efficacy data on February 17, 2016, for Aerie's second Phase 3 registration trial for Rhopressa(TM) QD, indicating that Rhopressa(TM) QD had a positive safety profile with sustained efficacy through the 12-month period. The Company expects to submit the NDA for Rhopressa(TM) QD in the third quarter of 2016. Management will host a conference call and provide accompanying slides to discuss this update at 5:00 p.m. ET today.
AERI: 17.35 (-0.19)
Glaucoma - Pipeline Review - Comparative Analysis, Therapeutics Assessment, Mechanism of Action & Route of Administration
M2 - Fri Jan 29, 5:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/7v2mrr/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AC Immune SA - Acadia Pharmaceuticals Inc. - Advanced Refractive Technologies, Inc. - Aerie Pharmaceuticals, Inc. - Allergan Plc - Altacor Limited - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Glaukos Corporation - GliaCure Inc. - Handok Inc. - Icon Bioscience, Inc. - IMMD Inc. - InMed Pharmaceuticals Inc. - Inotek Pharmaceuticals Corporation - (30 Others) Key Topics Covered: - Introduction - Glaucoma Overview - Therapeutics Development - Pipeline Products for Glaucoma - Overview - Pipeline Products for Glaucoma - Comparative Analysis - Glaucoma - Therapeutics under Development by Companies - Glaucoma - Therapeutics under Investigation by Universities/Institutes - Glaucoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Glaucoma - Products under Development by Companies - Glaucoma - Products under Investigation by Universities/Institutes - Glaucoma - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/7v2mrr/glaucoma
CANF: 2.10 (+0.03), AGN: 252.95 (-2.61), ACAD: 37.04 (+0.30), ITEK: 9.48 (-0.01), GILD: 79.47 (-1.77), GKOS: 34.96 (+0.21), AERI: 17.35 (-0.19), CLBS: 5.54 (+0.08)
Roche/AbbVie's Leukemia Drug Gets Breakthrough Status
Zacks Equity Research - Zacks Investment Research - Thu Jan 21, 2:00PM CST
Roche Holding AG (RHHBY) announced that the FDA has granted Breakthrough Therapy designation to venetoclax in combination with MabThera/Rituxan (rituximab) for the treatment of relapsed or refractory chronic lymphocytic leukemia.
AERI: 17.35 (-0.19), ABBV: 66.23 (+1.51), CORT: 5.80 (-0.06)
Synthetic Biologics Posts Encouraging Data on SYN-010
Zacks Equity Research - Zacks Investment Research - Wed Jan 20, 2:20PM CST
Synthetic Biologics, Inc. (SYN) announced encouraging data from the second phase II study on SYN-010 for the treatment of irritable bowel syndrome with constipation.
SYN: 1.75 (-0.03), AERI: 17.35 (-0.19), BXLT: 46.02 (-0.18), ANIK: 49.92 (+0.70)
The Zacks Analyst Blog Highlights: Aerie Pharmaceuticals, United Therapeutics, Pacira Pharmaceuticals, Ohr Pharmaceutical and Infinity Pharmaceuticals
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 8:30AM CST
The Zacks Analyst Blog Highlights: Aerie Pharmaceuticals, United Therapeutics, Pacira Pharmaceuticals, Ohr Pharmaceutical and Infinity Pharmaceuticals
UTHR: 121.01 (+2.02), AERI: 17.35 (-0.19), INFI: 1.68 (+0.06), OHRP: 2.73 (-0.02), PCRX: 36.25 (-1.22)
Aerie Pharmaceuticals to Announce Second Quarter 2016 Financial Results and Host Conference Call on Wednesday, August 3, 2016
BusinessWire - Wed Jul 27, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), (the "Company"
, announced today that its second quarter 2016 financial results will be released after the market closes on Wednesday, August 3, 2016. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company's financial results and provide a general business and strategic update. AERI: 17.35 (-0.19)
Aerie Pharmaceuticals Completes Enrollment of Rocket 4 Phase 3 Clinical Trial of Rhopressa(TM)(netarsudil ophthalmic solution) 0.02%
BusinessWire - Thu Jun 16, 5:30AM CDT
---Rocket 4 Designed for EU Filing; Not Required for US NDA Filing-
AERI: 17.35 (-0.19)
Aerie Pharmaceuticals to Participate in Two Investor Conferences in June
BusinessWire - Thu Jun 02, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that company management will present an overview of the company at the following conferences in June.
AERI: 17.35 (-0.19)
Aerie Pharmaceuticals Completes Enrollment of Mercury 1 Phase 3 Registration Trial of Roclatan(TM)(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
BusinessWire - Thu May 05, 5:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced the completion of patient enrollment in the Company's initial Phase 3 registration trial ("Mercury 1"
of Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Roclatan(TM) is a fixed dose combination of Aerie drug Rhopressa(TM) (netarsudil ophthalmic solution) 0.02% and latanoprost, the most widely prescribed PGA (prostaglandin analogue). Mercury 1 has total enrollment of approximately 690 patients in this three-arm study, designed to demonstrate superiority of Roclatan(TM) to each of its two components, all dosed once daily in the evening. The range for the primary endpoint evaluates patients with maximum baseline IOPs ranging from above 20 to below 36 mmHg (millimeters of mercury). Mercury 1, which commenced in September 2015 is a twelve-month safety trial with a 90-day interim efficacy readout that is expected in the third quarter of 2016. In March 2016, the Company commenced a second Phase 3 registration trial for Roclatan(TM), Mercury 2, which is a 90-day efficacy trial, and also plans to commence in the first half of 2017 a third Phase 3 clinical trial for Roclatan(TM), named Mercury 3, which will be designed to facilitate regulatory approval and commercialization in Europe. AERI: 17.35 (-0.19)
Aerie Pharmaceuticals to Present at the Bank of America Merrill Lynch 2016 Health Care Conference
BusinessWire - Wed May 04, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq: AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the Bank of America Merrill Lynch 2016 Health Care Conference on Wednesday, May 11, 2016 at 3:00 p.m. Pacific Time in Las Vegas, NV. Dr. Anido will provide an Aerie overview and business update.
AERI: 17.35 (-0.19)
Aerie (AERI) Q1 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Tue May 03, 7:57AM CDT
Aerie Pharmaceuticals, Inc. (AERI) posted a first-quarter 2016 loss of 85 cents per share, wider than both the Zacks Consensus Estimate of a loss of 66 cents and the year-ago loss of 70 cents.
GILD: 79.47 (-1.77), SHPG: 194.12 (+2.69), AERI: 17.35 (-0.19), AEGR: 1.44 (-0.03)
Aerie reports 1Q loss
Automated Insights - Mon May 02, 3:47PM CDT
IRVINE, Calif. (AP) _ Aerie Pharmaceuticals Inc. (AERI) on Monday reported a loss of $22.7 million in its first quarter.
AERI: 17.35 (-0.19)
Aerie Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update
BusinessWire - Mon May 02, 3:01PM CDT
--Mercury 1 Phase 3 Topline Readout for Roclatan(TM) (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% Also Expected in 3Q 2016
AERI: 17.35 (-0.19)
Drug Stocks Q1 Earnings Preview: AEGR, AERI, MACK, PRTA
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:04AM CDT
The going has been quite satisfactory as we stand in the thick of the first earnings season of the year.
MACK: 5.80 (+0.19), BIIB: 289.93 (+0.90), ABT: 44.75 (+0.30), JNJ: 125.23 (+0.77), AERI: 17.35 (-0.19), AEGR: 1.44 (-0.03), PRTA: 55.05 (-0.36)
Aerie (AERI): Can the Stock Pull a Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 5:41PM CDT
Aerie Pharmaceuticals, Inc. (AERI) is scheduled to report first-quarter 2016 results after the market closes on May 2.
GILD: 79.47 (-1.77), AERI: 17.35 (-0.19), AMGN: 172.03 (+0.75), SNY: 42.63 (+0.03)
Aerie Pharmaceuticals to Announce First Quarter 2016 Financial Results and Host Conference Call on Monday, May 2, 2016
BusinessWire - Mon Apr 25, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), (the "Company"
, announced today that its first quarter 2016 financial results will be released after the market closes on Monday, May 2, 2016. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company's financial results and provide a general business and strategic update. AERI: 17.35 (-0.19)
Will Aerie Pharmaceuticals (AERI) Continue to Surge Higher?
Zacks Equity Research - Zacks Investment Research - Wed Apr 13, 7:03AM CDT
As of late, it has definitely been a great time to be an investor in Aerie Pharmaceuticals, Inc. (AERI)
AERI: 17.35 (-0.19)
Aerie Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference
BusinessWire - Tue Apr 05, 6:30AM CDT
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, today announced that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present at the 15th Annual Needham Healthcare Conference on Tuesday, April 12, 2016 at 3:00 p.m. Eastern Time in New York, NY. Dr. Anido will provide an Aerie overview and business update.
AERI: 17.35 (-0.19)
Aerie Starts Dosing in Registration Trial Mercury 2 on Roclatan
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 3:25PM CDT
Aerie Pharmaceuticals, Inc. (AERI) announced the initiation of dosing in the second phase III registration trial, Mercury 2, on its pipeline candidate, Roclatan 0.02%/0.005%.
SCMP: 11.75 (+0.07), AERI: 17.35 (-0.19), CORT: 5.80 (-0.06)
Aerie Pharmaceuticals Initiates Second Phase 3 Registration Trial of Roclatan(TM)(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
BusinessWire - Mon Mar 28, 5:30AM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) ("Aerie" or the "Company"
, a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today announced that on March 24, dosing commenced of the first patients enrolled in Mercury 2, the Company's second Phase 3 registration trial of Roclatan(TM)(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. Roclatan(TM) is a fixed dose combination of Aerie product candidate Rhopressa(TM) (netarsudil ophthalmic solution) 0.02% and latanoprost, the most widely prescribed PGA (prostaglandin analogue). Aerie estimates total enrollment of approximately 690 patients in this three-arm 90-day efficacy study, comparing once-daily Roclatan(TM) for superiority to each of its two components, all dosed once daily in the evening. Patients will be evaluated with maximum baseline IOPs ranging from above 20 to below 36 mmHg (millimeters of mercury). The first Phase 3 registration trial for Roclatan(TM), named Mercury 1, commenced in September of 2015. Mercury 1, which is also a superiority trial with the same comparators as Mercury 2, is a 12-month safety trial with a 90-day interim efficacy readout. The Company also plans to commence in the first half of 2017 a third Phase 3 trial for Roclatan(TM), named Mercury 3, which will be for the sole purpose of facilitating regulatory approval and commercialization in Europe. AERI: 17.35 (-0.19)
Aerie Pharmaceuticals Reports Update on Positive Safety Results for Rhopressa(TM) QD (netarsudil ophthalmic solution) 0.02%
BusinessWire - Thu Mar 17, 3:01PM CDT
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported an update including further details on the safety profile for Rhopressa(TM) QD, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The Company previously reported interim topline 12-month safety and efficacy data on February 17, 2016, for Aerie's second Phase 3 registration trial for Rhopressa(TM) QD, indicating that Rhopressa(TM) QD had a positive safety profile with sustained efficacy through the 12-month period. The Company expects to submit the NDA for Rhopressa(TM) QD in the third quarter of 2016. Management will host a conference call and provide accompanying slides to discuss this update at 5:00 p.m. ET today.
AERI: 17.35 (-0.19)
Glaucoma - Pipeline Review - Comparative Analysis, Therapeutics Assessment, Mechanism of Action & Route of Administration
M2 - Fri Jan 29, 5:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/7v2mrr/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned: - AC Immune SA - Acadia Pharmaceuticals Inc. - Advanced Refractive Technologies, Inc. - Aerie Pharmaceuticals, Inc. - Allergan Plc - Altacor Limited - Amakem NV - Asahi Kasei Pharma Corp. - AUS Bio Limited - Bausch & Lomb Incorporated - Bionure Farma, S.L. - Caladrius Biosciences, Inc. - Can-Fite BioPharma Ltd. - China Grand Wuhan General Pharmaceutical Research Institute - D. Western Therapeutics Institute, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - F. Hoffmann-La Roche Ltd. - Gene Signal International SA - Gilead Sciences, Inc. - Glaukos Corporation - GliaCure Inc. - Handok Inc. - Icon Bioscience, Inc. - IMMD Inc. - InMed Pharmaceuticals Inc. - Inotek Pharmaceuticals Corporation - (30 Others) Key Topics Covered: - Introduction - Glaucoma Overview - Therapeutics Development - Pipeline Products for Glaucoma - Overview - Pipeline Products for Glaucoma - Comparative Analysis - Glaucoma - Therapeutics under Development by Companies - Glaucoma - Therapeutics under Investigation by Universities/Institutes - Glaucoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Glaucoma - Products under Development by Companies - Glaucoma - Products under Investigation by Universities/Institutes - Glaucoma - Companies Involved in Therapeutics Development For more information visit http://www.researchandmarkets.com/research/7v2mrr/glaucoma
CANF: 2.10 (+0.03), AGN: 252.95 (-2.61), ACAD: 37.04 (+0.30), ITEK: 9.48 (-0.01), GILD: 79.47 (-1.77), GKOS: 34.96 (+0.21), AERI: 17.35 (-0.19), CLBS: 5.54 (+0.08)
Roche/AbbVie's Leukemia Drug Gets Breakthrough Status
Zacks Equity Research - Zacks Investment Research - Thu Jan 21, 2:00PM CST
Roche Holding AG (RHHBY) announced that the FDA has granted Breakthrough Therapy designation to venetoclax in combination with MabThera/Rituxan (rituximab) for the treatment of relapsed or refractory chronic lymphocytic leukemia.
AERI: 17.35 (-0.19), ABBV: 66.23 (+1.51), CORT: 5.80 (-0.06)
Synthetic Biologics Posts Encouraging Data on SYN-010
Zacks Equity Research - Zacks Investment Research - Wed Jan 20, 2:20PM CST
Synthetic Biologics, Inc. (SYN) announced encouraging data from the second phase II study on SYN-010 for the treatment of irritable bowel syndrome with constipation.
SYN: 1.75 (-0.03), AERI: 17.35 (-0.19), BXLT: 46.02 (-0.18), ANIK: 49.92 (+0.70)
The Zacks Analyst Blog Highlights: Aerie Pharmaceuticals, United Therapeutics, Pacira Pharmaceuticals, Ohr Pharmaceutical and Infinity Pharmaceuticals
Zacks Equity Research - Zacks Investment Research - Tue Jan 19, 8:30AM CST
The Zacks Analyst Blog Highlights: Aerie Pharmaceuticals, United Therapeutics, Pacira Pharmaceuticals, Ohr Pharmaceutical and Infinity Pharmaceuticals
UTHR: 121.01 (+2.02), AERI: 17.35 (-0.19), INFI: 1.68 (+0.06), OHRP: 2.73 (-0.02), PCRX: 36.25 (-1.22)
